Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Warning Letters Lifted, Clearing Path For CRM, Neurostim PMAs

This article was originally published in The Gray Sheet

Executive Summary

A barrier to FDA approval for several of Medtronic's core product candidates was lifted with the firm's announcement March 9 that longstanding warning letters had been resolved.

You may also be interested in...



FDA To Meet With Medtronic On Drug Pump Risks; Warning Letter Sent

The agency posted a warning letter to Medtronic Aug. 21 citing the firm for multiple quality system deviations, including lapses in its efforts to address a failure risk for the SynchroMed II drug infusion pump.

New Products In Brief

Medtronic’s Protecta

New Products In Brief

Medtronic’s Protecta

Topics

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel